Overview Dividends

(HRMY) Harmony Biosciences Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4131971040

Wakix, Pitolisant, BP1.15205, HBS-102, Zyn-002

HRMY EPS (Earnings per Share)

EPS Growth (3Y CAGR): 12.04%
EPS Trend (3Y Correlation): 30.4%

HRMY Revenue

Revenue Growth (3Y CAGR): 25.47%
Revenue Trend (3Y Correlation): 94.5%

Risk via 10d forecast
Volatility	45.0%
Value at Risk 5%th	65.5%
Relative Tail Risk	-11.63%

Reward TTM
Sharpe Ratio	0.06
Alpha	-13.64

Character TTM
Hurst Exponent	0.451
Beta	0.524
Beta Downside	0.478

Drawdowns 3y
Max DD	68.48%
Mean DD	42.57%
Median DD	44.62%

Description: HRMY Harmony Biosciences Holdings November 10, 2025

Harmony Biosciences Holdings (NASDAQ: HRMY) is a commercial-stage biotech focused on rare-neurology therapeutics in the U.S. Its flagship product, WAKIX (pitolisant), is an orexin-2 receptor antagonist approved for excessive daytime sleepiness in adult narcolepsy. The company is expanding the pitolisant platform into Phase 3 for Prader-Willi syndrome, Phase 2 for myotonic dystrophy type 1, and early-stage formulations (GR and HD). Additional pipelines include an orexin-2 agonist (BP1.15205), an MCHR1 antagonist (HBS-102), a transdermal cannabidiol (ZYN-002) in Phase 3 for Fragile X and 22q-Deletion syndromes, and serotonin-based agents (EPX-100, EPX-200) targeting severe epileptic encephalopathies.

Key metrics (as of the most recent 10-Q) show cash and equivalents of roughly $70 million, giving the firm ~12 months of runway at current burn rates. WAKIX generated ≈ $30 million in 2023 sales, reflecting a modest but growing share of the U.S. narcolepsy market, which is projected to reach > $1 billion by 2028 (≈ 9 % CAGR). The broader rare-neurology sector benefits from higher pricing power and accelerated regulatory pathways, supporting premium valuation multiples for companies with multiple late-stage candidates.

If you want a data-rich snapshot of HRMY’s valuation, risk profile, and peer benchmarks, the ValueRay platform provides a concise, actionable overview that can help you assess whether the upside justifies the current uncertainty.

HRMY Stock Overview

Market Cap in USD	1,810m
Sub-Industry	Pharmaceuticals
IPO / Inception	2020-08-19
Return 12m vs S&P 500	-11.0%
Analyst Rating	4.33 of 5

HRMY Dividends

Currently no dividends paid

HRMY Growth Ratios

CAGR 3y	-15.24%
CAGR/Max DD Calmar Ratio	-0.22
CAGR/Mean DD Pain Ratio	-0.36
Current Volume	760.1k
Average Volume	766.1k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (185.7m TTM) > 0 and > 6% of Revenue (6% = 49.6m TTM)

FCFTA 0.25 (>2.0%) and ΔFCFTA 0.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 74.51% (prev 52.96%; Δ 21.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.25 (>3.0%) and CFO 297.6m > Net Income 185.7m (YES >=105%, WARN >=100%)

Net Debt (-477.3m) to EBITDA (264.0m) ratio: -1.81 <= 3.0 (WARN <= 3.5)

Current Ratio 3.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (58.7m) change vs 12m ago 1.06% (target <= -2.0% for YES)

Gross Margin 77.70% (prev 78.65%; Δ -0.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 77.32% (prev 73.47%; Δ 3.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.68 (EBITDA TTM 264.0m / Interest Expense TTM 15.3m) >= 6 (WARN >= 3)

Altman Z'' 5.62

(A) 0.51 = (Total Current Assets 838.8m - Total Current Liabilities 223.4m) / Total Assets 1.21b

(B) 0.11 = Retained Earnings (Balance) 138.4m / Total Assets 1.21b

(D) 0.37 = Book Value of Equity 138.8m / Total Liabilities 373.1m

Total Rating: 5.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 91.66

1. Piotroski 6.0pt = 1.0

2. FCF Yield 22.71% = 5.0

3. FCF Margin 35.95% = 7.50

4. Debt/Equity 0.20 = 2.48

5. Debt/Ebitda -1.81 = 2.50

6. ROIC - WACC (= 11.86)% = 12.50

7. RoE 24.86% = 2.07

8. Rev. Trend 94.53% = 7.09

9. EPS Trend 30.44% = 1.52

What is the price of HRMY shares?

As of November 14, 2025, the stock is trading at USD 34.29 with a total of 760,120 shares traded.
Over the past week, the price has changed by +10.83%, over one month by +30.08%, over three months by -6.49% and over the past year by +1.33%.

Is Harmony Biosciences Holdings a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Harmony Biosciences Holdings (NASDAQ:HRMY) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 91.66 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRMY is around 29.63 USD . This means that HRMY is currently overvalued and has a potential downside of -13.59%.

Is HRMY a buy, sell or hold?

Harmony Biosciences Holdings has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy HRMY.

Strong Buy: 5
Buy: 3
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HRMY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	44.6	29.9%
Analysts Target Price	44.6	29.9%
ValueRay Target Price	33	-3.7%

HRMY Fundamental Data Overview November 10, 2025

Market Cap USD = 1.81b (1.81b USD * 1.0 USD.USD)
P/E Trailing = 9.9148
P/E Forward = 6.1275
P/S = 2.1917
P/B = 1.9915
Beta = 0.821
Revenue TTM = 825.9m USD
EBIT TTM = 240.1m USD
EBITDA TTM = 264.0m USD
Long Term Debt = 163.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.8m USD (from shortTermDebt, last quarter)
Debt = 169.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -477.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.31b USD (1.81b + Debt 169.7m - CCE 672.6m)
Interest Coverage Ratio = 15.68 (Ebit TTM 240.1m / Interest Expense TTM 15.3m)
FCF Yield = 22.71% (FCF TTM 296.9m / Enterprise Value 1.31b)
FCF Margin = 35.95% (FCF TTM 296.9m / Revenue TTM 825.9m)
Net Margin = 22.48% (Net Income TTM 185.7m / Revenue TTM 825.9m)
Gross Margin = 77.70% ((Revenue TTM 825.9m - Cost of Revenue TTM 184.2m) / Revenue TTM)
Gross Margin QoQ = 75.09% (prev 80.97%)
Tobins Q-Ratio = 1.08 (Enterprise Value 1.31b / Total Assets 1.21b)
Interest Expense / Debt = 2.13% (Interest Expense 3.62m / Debt 169.7m)
Taxrate = 24.63% (16.6m / 67.5m)
NOPAT = 181.0m (EBIT 240.1m * (1 - 24.63%))
Current Ratio = 3.75 (Total Current Assets 838.8m / Total Current Liabilities 223.4m)
Debt / Equity = 0.20 (Debt 169.7m / totalStockholderEquity, last quarter 835.1m)
Debt / EBITDA = -1.81 (Net Debt -477.3m / EBITDA 264.0m)
Debt / FCF = -1.61 (Net Debt -477.3m / FCF TTM 296.9m)
Total Stockholder Equity = 747.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.37% (Net Income 185.7m / Total Assets 1.21b)
RoE = 24.86% (Net Income TTM 185.7m / Total Stockholder Equity 747.0m)
RoCE = 26.39% (EBIT 240.1m / Capital Employed (Equity 747.0m + L.T.Debt 163.0m))
RoIC = 20.26% (NOPAT 181.0m / Invested Capital 893.3m)
WACC = 8.40% (E(1.81b)/V(1.98b) * Re(9.04%) + D(169.7m)/V(1.98b) * Rd(2.13%) * (1-Tc(0.25)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF Debug] Terminal Value 78.27% ; FCFE base≈266.2m ; Y1≈328.4m ; Y5≈560.3m
Fair Price DCF = 137.5 (DCF Value 7.92b / Shares Outstanding 57.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 30.44 | EPS CAGR: 12.04% | SUE: 1.91 | # QB: 2
Revenue Correlation: 94.53 | Revenue CAGR: 25.47% | SUE: 3.84 | # QB: 1

Additional Sources for HRMY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle